TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
In a recent transaction, Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company with a market capitalization of approximately $950 million, saw Chief Financial Officer Justin A. Renz sell 7,218 shares of the company’s common stock. The shares were sold on May 20, 2025, at an average price of $4.0814 per share, amounting to a total transaction value of $29,459. According to InvestingPro analysis, the stock is currently trading below its Fair Value, despite challenging market conditions that have led to a 46% decline over the past year.
The sale was executed as part of an automatic sell-to-cover arrangement linked to the vesting of restricted stock units (RSUs), specifically to cover applicable withholding taxes. Following this transaction, Renz holds 416,089 shares of Ardelyx stock. This figure includes an additional 659 shares acquired under the Ardelyx Employee Stock Purchase Plan in February 2025. InvestingPro data shows the company maintains strong liquidity with a current ratio of 4.12, indicating robust short-term financial health. For deeper insights into Ardelyx’s financial position and detailed valuation metrics, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Ardelyx Inc . reported its first-quarter 2025 earnings, revealing a net loss of $0.17 per share, which fell short of the forecasted loss of $0.11 per share. The company’s revenue was $74.1 million, missing the expected $78.09 million, although it marked a 61% increase year-over-year. Despite the earnings miss, Ardelyx’s IBSRELA and XPOVIO showed strong sales growth, with IBSRELA net sales rising by 57% and XPOVIO by 55% compared to the previous year. Raymond (NSE:RYMD) James downgraded Ardelyx’s stock rating from "Strong Buy" to "Outperform" and lowered the price target from $13.00 to $11.00, citing concerns about future growth and increased SG&A expenses. Ardelyx presented new data at the Digestive Disease Week Conference on IBSRELA, emphasizing its benefits for IBS-C patients and its safety profile. The company remains optimistic about its future, maintaining its 2025 sales guidance for IBSRELA and XPOVIO, despite the challenges faced in the market. Ardelyx continues to explore corporate development opportunities to enhance its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.